Patients with STS should be included in immune-checkpoint inhibitor trials based on their histotype (UPS, DDLPS) and on their TME [PD-L1 and other ICP expression, CD8+ T cell infiltrate, presence of TLS, (Figure 2)]. This evidence concerns the gene CD8A and telomere syndrome.